Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Sun Pharma

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1…

The Economic Times

Reliance, financials and defence top investment picks as market leadership broadens: Rahul Shah

Reliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant returns. Small banks are also attractive due to improving fundamentals and valuations. While IT valuations are cheap, earnings growth is a concern. Financials, particularly large private banks and NBFCs, remain a…

The Economic Times

Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGC

Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despite this, the broader recovery trend remains intact above 23,700. Several companies like Sun Pharma, Tata Motors, and ONGC are in focus due to significant business developments, including acquisitions,…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transaction

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash deal. This strategic move aims to bolster Sun Pharma's product offerings. Innovcare, which markets pharmaceutical drugs, nutraceuticals, and cosmeceuticals, reported steady revenue growth in recent fiscal years. The transaction, expected to…

The Economic Times

Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplash

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic demand and positive global healthcare trends. Analysts see long-term growth potential from aging populations and innovation. Emerging opportunities from supply chain diversification away from China also present a positive outlook for…

The Economic Times

SBI in $1 billion funding for Sun Pharma’s US deal

State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding…

The Economic Times

Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmer

Indian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their effect on peace deal hopes. Broader markets are performing better. India VIX, a volatility measure, dropped. Top Sensex losers included HDFC Bank and Infosys. Sun Pharma shares led…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.

The Economic Times

Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the…

The Economic Times

Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap plays

Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries is highlighted as a strong recovery story, while Nykaa and Honasa are viewed cautiously. The pharma sector continues its outperformance, with Sun Pharma and Aurobindo Pharma looking attractive.

The Economic Times

Stocks in news: ITC, LIC, Sun Pharma, Maruti Suzuki, Fino Payments Bank

Benchmark indices experienced a negative close on Thursday, marked by volatile trade and profit booking. Analysts anticipate the Nifty to continue its consolidation between 23,200 and 23,900. Several companies, including ITC, LIC, Sun Pharma, Maruti Suzuki, and Fino Payments Bank, are in focus due to Q4 results and other developments.

The Economic Times

Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?

Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages highlight US portfolio strength, new launches like Unloxcyt, and a steady margin outlook despite higher R&D spending, with EBITDA growth supported by diversified global business momentum…

The Economic Times

Jio Financial, ITC Hotels and Manappuram Finance among stocks bought and sold by mutual funds in April

Mutual funds injected Rs 30,600 crore into Indian equities in April, with significant buying in ICICI Bank, SBI, and Sun Pharma. Key reductions were observed in Wipro, HDFC Bank, and Hindalco Industries across large, mid, and smallcap segments. This active portfolio management reflects ongoing strategic shifts by fund managers.

The Economic Times

When the world's an oyster for Sun (Pharma)

Indian companies are increasingly making bold acquisitions abroad. Sun Pharma's deal signals a new era of deliberate empire-building. This shift from tentative deals to strategic bets is crucial for global relevance. Successful acquisitions require clear intent, respect for acquired assets, integration discipline, financial courage, and a long-term mindset.

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

Times Life

7 Things That Will Get Cheaper After Budget 2026

Most budgets promise relief. Very few actually change what you pay in real life. Budget 2026 is one of those rare ones that works quietly. There were no dramatic tax cuts, no loud announcements, and no instant price drops flashed across screens. Yet, beneath the fine print, the government made…

Salon

FDA let risky drugs into US

The FDA let risky drugs from banned foreign plants into the United States

The Times of India

Quality lapse by major pharma firms in India, 53 drugs and leading companies under scrutiny

India's drug regulator, the Central Drugs Standards Control Organisation (CDSCO), has listed more than 50 drugs as "Not of Standard Quality (NSQ) Alert" in its latest monthly report. This list includes widely used medicines such as calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines.

The Guardian - UK

Interpol candidate accused of role in kidnap of Indian businessmen

Zambia’s Mubita Nawa, who is on shortlist for top job, is accused of involvement in an attempted extortion in 2022

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

Sun Pharma says it relied on Google Maps to show company lies outside Vedanthangal bird sanctuary limits

Sun Pharmaceuticals has informed the southern bench of the National Green Tribunal (NGT) that it relied on Google Maps to submit the location of its manufacturing plant in Sathamai in the pre-feasibility report submitted as part of the environmental clearance application

ABC News

Drug giant Sun Pharma warned over manufacturing violations. What does this mean for Australia?

Questions have been raised about how Australia ensures the quality of its imported medicines after a major pharmaceutical company was warned over lapses in contamination control and manufacturing practices.

The Times of India

What is the MSCI India Index and why it matters

NEW DELHI: Global indices service provider MSCI had earlier this month announced a couple of inclusion and exclusion, along with changes in weightages of a few Indian stocks, which has influenced flows in these stocks. While it has added four stocks to its MSCI India index, namely Tata Elxsi, Adani…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.